Clinical Trial Update: A Safety and Tolerability Study of Dapivirine (TMC120) Vaginal Microbicide Gel [Phase 1, Phase 2]

View source ↗

Summary

This trial update reports safety and tolerability findings from Phase 1/2 studies of a dapivirine vaginal gel (TMC120) intended to reduce HIV infection risk.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Dapivirine vaginal gel (TMC120) (dapivirine)

Snippet

Sponsor: International Partnership for Microbicides, Inc. | Conditions: HIV Infections | Phase 1, Phase 2 | Status: COMPLETED